EP4720060A1 - Prmt5-inhibitoren - Google Patents

Prmt5-inhibitoren

Info

Publication number
EP4720060A1
EP4720060A1 EP24727762.7A EP24727762A EP4720060A1 EP 4720060 A1 EP4720060 A1 EP 4720060A1 EP 24727762 A EP24727762 A EP 24727762A EP 4720060 A1 EP4720060 A1 EP 4720060A1
Authority
EP
European Patent Office
Prior art keywords
methyl
carboxamide
amino
quinolin
furo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24727762.7A
Other languages
English (en)
French (fr)
Inventor
Adam RADZIMIERSKI
Aneta BOBOWSKA
Aleksandra Julia WIECKOWSKA
Julia Krzywik
Nicolas Félix Pierre BOUTARD
Didier Pez
Sujit SASMAL
Martin Edward Swarbrick
Marta Magdalena OLSZAK-PLACHTA
Pavlo SOLOMONOVICH LEBED
Marianna GIRARDI
Szymon PALUCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ryvu Therapeutics SA
Original Assignee
Ryvu Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ryvu Therapeutics SA filed Critical Ryvu Therapeutics SA
Publication of EP4720060A1 publication Critical patent/EP4720060A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP24727762.7A 2023-05-24 2024-05-23 Prmt5-inhibitoren Pending EP4720060A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23461596 2023-05-24
EP24169443 2024-04-10
PCT/EP2024/064279 WO2024240894A1 (en) 2023-05-24 2024-05-23 Prmt5 inhibitors

Publications (1)

Publication Number Publication Date
EP4720060A1 true EP4720060A1 (de) 2026-04-08

Family

ID=91193326

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24727762.7A Pending EP4720060A1 (de) 2023-05-24 2024-05-23 Prmt5-inhibitoren

Country Status (7)

Country Link
EP (1) EP4720060A1 (de)
KR (1) KR20260015209A (de)
CN (1) CN121712770A (de)
AU (1) AU2024275020A1 (de)
IL (1) IL324764A (de)
MX (1) MX2025013985A (de)
WO (1) WO2024240894A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240101570A1 (en) * 2020-11-24 2024-03-28 Amgen Inc. Tricyclic carboxamide derivatives as prmt5 inhibitors
AU2022217791A1 (en) * 2021-02-04 2023-08-17 Amgen Inc. Tricyclic-amido-bicyclic prmt5 inhibitors
US20240368153A1 (en) * 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
WO2024074611A1 (en) * 2022-10-05 2024-04-11 Ryvu Therapeutics S.A. Prmt5 inhibitors

Also Published As

Publication number Publication date
MX2025013985A (es) 2026-01-07
CN121712770A (zh) 2026-03-20
WO2024240894A1 (en) 2024-11-28
AU2024275020A1 (en) 2025-11-13
KR20260015209A (ko) 2026-02-02
IL324764A (en) 2026-01-01

Similar Documents

Publication Publication Date Title
TWI734693B (zh) 群落刺激因子-１受體（ｃｓｆ-１ｒ）抑制劑
US10000507B2 (en) Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
EP3466929B1 (de) Als pdk1-inhibitoren nützliche heterocyclische verbindungen
WO2024153180A1 (zh) 杂环类化合物、其药物组合物及其用途
CN116262749A (zh) 一类芳杂环取代的化合物及其制备方法和用途
EP3168219B1 (de) Pyridonderivat mit tetrahydropyranyl-methylgruppe
WO2022228399A1 (zh) 三并环类usp1抑制剂及其用途
JP7405468B2 (ja) Ｂｒｄ４阻害活性を有する化合物、その調製方法および用途
CN117062816A (zh) 三环-酰胺-双环prmt5抑制剂
KR20210151833A (ko) Eed 및 prc2 조절제로서 마크로사이클릭 아졸로피리딘 유도체
CN108698996A (zh) 可用于治疗癌症和糖尿病的6-芳基-4-吗啉-1-基吡啶酮化合物
AU2024286830A1 (en) Wrn inhibitors
AU2024275020A1 (en) Prmt5 inhibitors
CN115611924A (zh) 一种pd-1/pd-l1抑制剂及其制备方法和用途
WO2024074611A1 (en) Prmt5 inhibitors
CN112839931A (zh) 1,2,3,4-四氢喹喔啉衍生物及其制备方法和应用
WO2025215153A1 (en) Prmt5 inhibitors
CA3156547C (en) Compound having brd4 inhibitory activity, preparation method therefor and use thereof
WO2025250620A1 (en) Tricyclic fused wrn inhibitors
WO2026015855A1 (en) Spirocyclic wrn inhibitors
EA047095B1 (ru) Соединение, обладающее ингибирующей активностью в отношении brd4, способ его получения и его применения
HK40045156A (en) 1,2,3,4-tetrahydroquinoxaline derivative, preparation method therefor and application thereof
HK40063493B (en) (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer
HK40063493A (en) (pyridin-2-yl)amine derivatives as tgf-beta r1 (alk5) inhibitors for the treatment of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR